Endothelial Growth Factors

• 

  Subject Areas on Research

  • Adaptive mechanisms that preserve cardiac function in mice without myoglobin. 
  • Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. 
  • Aged human muscle demonstrates an altered gene expression profile consistent with an impaired response to exercise. 
  • Ameroid constrictor versus hydraulic occluder: creation of hibernating myocardium. 
  • Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. 
  • Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. 
  • Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. 
  • Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer. 
  • Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. 
  • Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. 
  • Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization. 
  • Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. 
  • Differential expression of VEGF isoforms in mouse during development and in the adult. 
  • Direct myocardial revascularization and angiogenesis--how many patients might be eligible? 
  • Early wound healing exhibits cytokine surge without evidence of hypoxia. 
  • Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. 
  • Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: the role of VEGF(165). 
  • Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. 
  • Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. 
  • Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. 
  • Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. 
  • Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiomics. 
  • Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? 
  • HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. 
  • Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. 
  • Hypoxia and Lou Gehrig. 
  • Induction and maintenance of increased VEGF protein by chronic motor nerve stimulation in skeletal muscle. 
  • Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. 
  • Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. 
  • Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. 
  • Long- and short-term effects of biological hydrogels on capsule microvascular density around implants in rats. 
  • Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. 
  • Molecular profile and partial functional analysis of novel endothelial cell-derived growth factors that regulate hematopoiesis. 
  • Myocardial gene transfer. 
  • PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. 
  • Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. 
  • Phase I study of recombinant human endostatin in patients with advanced solid tumors. 
  • Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. 
  • Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. 
  • Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. 
  • Radiation-induced hypoxia may perpetuate late normal tissue injury. 
  • Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. 
  • Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. 
  • Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. 
  • Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. 
  • Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. 
  • Synergy between tumor immunotherapy and antiangiogenic therapy. 
  • Technology evaluation: VEGF165 gene therapy, Valentis Inc. 
  • The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. 
  • The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expression. 
  • The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. 
  • Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. 
  • VEGF increases retinal vascular ICAM-1 expression in vivo. 
  • VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. 
  • Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. 
  • Vascular endothelial growth factor expression in pig latissimus dorsi myocutaneous flaps after ischemia reperfusion injury. 
  • Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. 
  • Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. 
  • Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. 
  • Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. 
  • Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. 
  • [A novel model for visualization of tumor cell-induced angiogenesis in vivo]. 
  • [Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway]. 
  • p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. 
• 

  Keywords of People

  • Warner, David Samuel, Distinguished Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology